Cost-Utility Analysis of Radiation Treatment Modalities for Intermediate-Risk Prostate Cancer.

Najlaa Alyamani Jiheon SongSasha van KatwykWalter P WodchisJulie RenaudAlain HaddadMiller MacPhersonMarc Gaudet

Published in: Current oncology (Toronto, Ont.) (2021)

Stereotactic body radiotherapy is the most cost-effective radiation treatment modality in treatment of intermediate-risk prostate cancer, while treatment toxicity and cost data are the key drivers of the cost-utility. Further work is required with long-term follow-up for SBRT.

Keyphrases

prostate cancer
radiation therapy
squamous cell carcinoma
radical prostatectomy
oxidative stress
early stage
machine learning
replacement therapy
locally advanced
big data